Review of type 2 diabetes pharmacotherapy in elderly patients, with GLP-1 agonists and DPP-4 inhibitors offering advantages of low hypoglycemia risk and weight neutrality/loss — important for frail older patients.
Key findingReview of type 2 diabetes pharmacotherapy in elderly patients, with GLP-1 agonists and DPP-4 inhibitors offering advantages of low hypoglycemia risk a
What the researchers found
Review of type 2 diabetes pharmacotherapy in elderly patients, with GLP-1 agonists and DPP-4 inhibitors offering advantages of low hypoglycemia risk and weight neutrality/loss — important for frail older patients.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2009.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Pharmacologic management of the older patient with type 2 diabetes mellitus.
The American journal of geriatric pharmacotherapy, 7(6), 324-42
Citation
Neumiller, Joshua J; Setter, Stephen M. (2009). Pharmacologic management of the older patient with type 2 diabetes mellitus.. The American journal of geriatric pharmacotherapy, 7(6), 324-42. https://doi.org/10.1016/j.amjopharm.2009.12.002